# US 2015/0147316 A1 · Cd33 antibodies and use of same to treat cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147316 A1
- Document ID: US20150147316A1
- Status: Published application
- Kind: A1
- Application number: 14/401,837
- Filed: 2013-05-15
- Published: 2015-05-28
- Earliest claimed: 2012-05-18
- Assignees: Seattle Genetics, Inc.
- Applicants: Seattle Genetics, Inc.
- Inventors: May Kung Sutherland; Maureen Ryan; Django Sussman; Patrick Burke; Scott Jeffrey
- Web page: https://patentgrep.com/patent/US20150147316A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

## Claims

### Claim 1

An isolated antibody that specifically binds to the human CD33 protein, wherein the antibody comprises three heavy chain complementarity determining regions (CDRs): heavy chain CDR1 consisting of SEQ ID NO:19, heavy chain CDR2 consisting of SEQ ID NO:20, and heavy chain CDR3 consisting of SEQ ID NO:21; and three light chain CDRs: light chain CDR1 consisting of SEQ ID NO:22, light chain CDR2 consisting of SEQ ID NO:23, and light chain CDR3 consisting of SEQ ID NO:24.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is selected from a murine antibody, a chimeric antibody, and a humanized antibody.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the antibody is a humanized 2H12 antibody.

### Claim 4 (depends on 3)

The humanized antibody of claim 3, wherein the antibody comprises a mature heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:18 provided that position H48 is occupied by I, position H66 is occupied by K, position H67 is occupied by A, position H69 is occupied by L, position H71 is occupied by A, and position H94 is occupied by S and a mature light chain variable region at least 90% identical to SEQ ID NO:8 provided position L22 is occupied by N, position L46 is occupied by T, position L69 is occupied by Q, and position L71 by Y, as determined by the Kabat numbering system.

### Claim 5 (depends on 3)

The humanized antibody of claim 3, comprising a mature heavy chain variable region having an amino acid sequence at least 95% identical to SEQ ID NO:18 and a mature light chain variable region at least 95% identical to SEQ ID NO:8.

### Claim 6 (depends on 3)

The humanized antibody of claim 3, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.

### Claim 7 (depends on 3)

The humanized antibody of claim 3, wherein the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcγ receptor relative to the natural human constant region.

### Claim 8 (depends on 2)

The humanized antibody of claim 2, wherein the heavy chain constant region is of IgG1 isotype.

### Claim 9 (depends on 3, 4, 5, 6)

The humanized antibody of claims 3-6, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:27 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:25.

### Claim 10 (depends on 3)

The humanized antibody of claim 3, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:29 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:25.

### Claim 11 (depends on 3)

The humanized antibody of claim 3, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:18 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO: 8.

### Claim 12

The antibody of any of the preceding claims, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 13 (depends on 12)

The antibody of claim 12, wherein the antibody is conjugated to a cytotoxic agent.

### Claim 14 (depends on 13)

The antibody of claim 13, wherein the cytotoxic agent is conjugated to the antibody via an enzyme cleavable linker.

### Claim 15 (depends on 13, 14)

The antibody of claim 13 or 14, wherein the cytotoxic agent is a DNA minor groove binder.

### Claim 16 (depends on 13, 14, 15)

The antibody of any of claims 13-15, wherein the cytotoxic agent has the formula

### Claim 17 (depends on 1)

The antibody of claim 1 having an association constant for human or cynomolgus monkey CD33 of 0.5 to 2×109 M−1.

### Claim 18

A method of treating a patient having or at risk of having a cancer that expresses CD33, comprising administering to the patient an effective regime of a humanized antibody of any of the preceding claims.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute promyelocytic leukemia (APL), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), a chronic myeloproliferative disorders, precursor B-cell acute lymphoblastic leukemia (preB-ALL), precursor T-cell acute lymphoblastic leukemia (preT-ALL), multiple myeloma (MM), mast cell disease, or myeloid Sarcoma.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a humanized or chimeric antibody of claim 1.

### Claim 21

A humanized antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to HI (SEQ ID NO:18) and a mature light chain variable region at least 90% identical to LG (SEQ ID NO:8).

### Claim 22 (depends on 21)

The humanized antibody of claim 21, comprising a mature heavy chain variable region having an amino acid sequence at least 95% identical to HI and a mature light chain variable region at least 95% identical to LG.

### Claim 23 (depends on 21, 22)

The humanized antibody of claim 21 or 22, provided that position H94 is occupied by S.

### Claim 24 (depends on 21, 22)

The humanized antibody of claim 21 or 22, provided that position H48, H66, H67, H69, H71 and H94 are occupied by I, K, A, L, A and S, and L22, L46, L69 and L71 are occupied by N, T, Q and Y.

### Claim 25 (depends on 21, 22, 23, 24)

The humanized antibody of any of claims 21-24, provided that any difference in the variable region frameworks of the mature heavy chain variable region and SEQ ID NO:18 are selected from the group consisting of position H48 occupied by I, position H66 occupied by K, position H67 occupied by A, position H69 occupied by L, position H71 occupied by A, position H94 occupied by S; and that any differences in the variable region frameworks of the mature light chain variable region and SEQ ID NO:8 are selected from the group consisting of position L22 occupied by N, position L46 occupied by T, position L69 occupied by Q, and position L71 occupied by Y.

### Claim 26 (depends on 21, 22, 23, 24, 25)

The humanized antibody of any of claims 21-25, wherein the 3 CDRs of the mature heavy chain variable region are those of SEQ ID NO:18 and the 3 CDRs of the mature light chain variable region are those of SEQ ID NO:8.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The humanized antibody of any of claims 21-26, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The humanized antibody of any of claims 21-27, wherein the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcγ receptor relative to the natural human constant region.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The humanized antibody of any of claims 21-28, wherein the heavy chain constant region is of IgG1 isotype.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 29)

The humanized antibody of any of claim 21-27 or 29, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:27 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:25.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 29)

The humanized antibody of any of claim 21-27 or 29, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:29 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:25.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The humanized antibody of any of claims 21-31 provided any differences in CDRs of the mature heavy chain variable region of SEQ ID NO:18 reside in positions H60-H65.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The humanized antibody of any of claims 21-32, wherein the mature heavy chain variable region has an amino acid sequence comprising SEQ ID NO:18 and the mature light chain variable region has an amino acid sequence comprising SEQ ID NO:8.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The humanized antibody of any of claims 21-33, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 35 (depends on 34)

The humanized antibody of claim 34, wherein the antibody is conjugated to a cytotoxic agent.

### Claim 36 (depends on 35)

The humanized antibody of claim 35, wherein the cytotoxic agent is conjugated to the antibody via an enzyme cleavable linker.

### Claim 37 (depends on 35, 36)

The humanized antibody of claim 35 or 36, wherein the cytotoxic agent is a DNA minor groove binder.

### Claim 38 (depends on 34, 35, 36, 37)

The humanized antibody of claim 34-37, wherein the cytotoxic agent has the formula

### Claim 39

A humanized antibody comprising a mature heavy chain variable region comprising the 3 CDRs of SEQ ID NO:18 and wherein positions H48, H66, H67, H69, H71 and H94 are occupied by I, K, A, L, A and S respectively, and a mature light chain variable region comprising the 3 CDRs of SEQ ID NO:8, and wherein positions L22, L46, L69 and L71 are occupied by N, T, Q and Y, respectively.

### Claim 40 (depends on 39)

The humanized antibody of claim 39, having an association constant for human or cynomolgus monkey CD33 of 0.5 to 2×109 M−1.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region as defined by any of claims 1-17 or claims 21-40.

### Claim 42 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method of treating a patient having or at risk of cancer, comprising administering to the patient an effective regime of a humanized antibody of any of claims 21-40.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer is acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute promyelocytic leukemia (APL), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), a chronic myeloproliferative disorders, precursor B-cell acute lymphoblastic leukemia (preB-ALL), precursor T-cell acute lymphoblastic leukemia (preT-ALL), multiple myeloma (MM), mast cell disease, or myeloid Sarcoma.

### Claim 44

A pharmaceutical composition comprising a humanized antibody of any preceding claim.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 39, 40)

A method of treating a patient having or at risk of having acute myeloid leukemia (AML), comprising administering to the patient an effective regime of a humanized antibody humanized antibody of any of claim 1-17, 21-33 or 39-40.

### Claim 46 (depends on 45)

The method of claim 45, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody is conjugated to a cytotoxic agent.

### Claim 48 (depends on 47)

The method of claim 47, wherein the cytotoxic agent is conjugated to the antibody via an enzyme cleavable linker.

### Claim 49 (depends on 47, 48)

The method of claim 47 or 48, wherein the cytotoxic agent is a DNA minor groove binder.

### Claim 50 (depends on 47, 48, 49)

The method of claims 47-49, wherein the cytotoxic agent has the formula
